Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- George Coukos, MD, PhD
University of Lausanne Hospitals
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Facility
Lausanne, Switzerland
- Research Facitlity
Phoenix, Arizona, United States
- Research Facility
New York, New York, United States
- Research Facility
Hilliard, Ohio, United States
- Research Facility
Providence, Rhode Island, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Dec 2015
- Primary completion
- 11 Dec 2018
- Completion
- 10 Jun 2021
- Last update posted
- 10 Oct 2022
- Registered enrollment
- 53
- Registry id
- NCT02431559
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.